HASBROUCK HEIGHTS, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that enrollment in the company's NX03-0040 US Phase 2 clinical trial of NX-1207 for localized prostate cancer is nearing completion with over 80% patients now enrolled. Based on current screening and enrollment rates, the company anticipates that enrollment will be completed in the near future. Initial top line study results are expected to be available approximately 2 months after completion of enrollment.
Help employers find you! Check out all the jobs and post your resume.
